CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

Inclusion Criteria:

1. Age 18-75 (≥ 18 years old, ≤ 75 years old), gender is not limited;
2. The subject voluntarily participates in the research and signs the "Informed Consent"by himself or his legal guardian;
3. According to the National Comprehensive Cancer Network (NCCN) T lymphocytic lymphoma (2020.V1)/acute lymphoblastic leukemia (2020. V1) practice guidelines, diagnosed withT-cell lymphoma;
4. Meet the diagnostic criteria for relapsed/refractory T-cell lymphoma, including any ofthe following:

1. Failure to obtain CR at the end of induction therapy; 2) Patients who have obtained CRhave blasts in peripheral blood or bone marrow (proportion >5%), or extramedullarydiseases; 5. Have not received antibody therapy within 2 weeks before cell therapy; 6. ECOGscore of 0-2; 7. The subject has no contraindications to peripheral apheresis; 8. Expectedsurvival time of more than 3 months.

Exclusion Criteria:

1. Those who have a history of allergy to any of the ingredients in cell products;
2. Laboratory tests for the following: including but not limited to, total serumbilirubin≧ 1.5mg/dl; Serum ALT or AST greater than 2.5 times the upper limit ofnormal; Blood creatinine≧ 2.0mg/dl; Platelet count≦ 10×109/L;
3. Patients with cardiac insufficiency who belong to class III or IV according to the NewYork Cardiology Association (NYHA) cardiac function grading standards; orechocardiography with left ventricular ejection fraction (LVEF) < 50%;
4. Abnormal lung function, blood oxygen saturation under indoor air < 92%;
5. Myocardial infarction, cardiac angioplasty or stenting, unstable angina, or otherserious clinical heart disease within 12 months before enrollment;
6. Grade 3 hypertension with poor control of blood pressure with medication;
7. Patients with other advanced tumors (those who are assessed as stable after treatmentof other tumors can be enrolled);
8. Previous head trauma, impaired consciousness, epilepsy, more serious cerebral ischemiaor cerebral hemorrhage disease;
9. Known central nervous system leukemia (CNS2 or CNS3), resistance to intrathecalchemotherapy injections and/or ongoing head and/or spinal radiation therapy; PreviousCNS history but has been effectively controlled to allow enrollment;
10. Patients with autoimmune diseases, immunodeficiency or other patients requiringimmunosuppressant therapy;
11. presence of uncontrolled, active infection;
12. Have previously used any CAR-T cell product or other genetically modified T celltherapy;
13. Live vaccination within 4 weeks prior to enrollment;
14. HIV, HBV, HCV and TPPA/RPR infections, and HBV carriers;
15. Subject has a history of alcoholism, drug addiction or mental illness;
16. The subject has participated in any other clinical research within 3 months beforejoining this clinical study;
17. Female subjects have any of the following conditions: a) are pregnant/lactating; or b)have plans to become pregnant during the trial; or c) are of childbearing potentialand unable to use effective contraception;
18. There are other circumstances in which the investigator believes that the subject isnot suitable for this study.